Description

LuciTirze 7.5mg Injection (Tirzepatide) – Uses, Side Effects, Dosage & Price in Pakistan

LuciTirze 7.5mg Injection (Tirzepatide) is a prescription injectable medicine containing tirzepatide, a dual GIP and GLP-1 receptor agonist. Tirzepatide is used in approved treatment settings for type 2 diabetes and, under specific product indications, chronic weight management in adults with obesity or overweight with certain weight-related conditions.

LuciTirze 7.5mg is administered as a subcutaneous injection once weekly. The 7.5mg strength is generally part of a gradual dose-escalation schedule rather than the usual starting dose. Treatment should therefore be initiated and adjusted by a qualified healthcare professional.

Tirzepatide can improve blood-glucose control by enhancing glucose-dependent insulin secretion and reducing glucagon levels. It also slows gastric emptying and can reduce appetite and food intake.

Patients looking for LuciTirze 7.5mg Injection in Pakistan can check product information, price, and availability through Impo Medic. Tirzepatide should only be used according to an appropriate prescription and treatment plan.

LuciTirze 7.5mg Injection (Tirzepatide) Uses

Tirzepatide has approved uses that depend on the specific branded product and regulatory jurisdiction.

Type 2 Diabetes

Tirzepatide is used alongside diet and exercise to improve blood-sugar control in patients with type 2 diabetes mellitus under approved treatment settings.

It may help reduce both fasting and post-meal blood glucose and can improve HbA1c when used appropriately.

Tirzepatide is not insulin. Patients who already use insulin or certain other diabetes medicines may require adjustments to their existing treatment because combining these medicines can increase the risk of hypoglycemia.

Weight Management

Tirzepatide is also approved under specific branded indications for chronic weight management in adults with obesity or adults who are overweight and have at least one weight-related medical condition.

For weight management, treatment is intended to be combined with a reduced-calorie diet and increased physical activity.

Tirzepatide should not be treated as a casual or cosmetic weight-loss injection. A healthcare professional should determine whether it is appropriate based on the patient’s health, body weight, medical history, and other medicines.

Obstructive Sleep Apnea

Under an approved tirzepatide weight-management indication, tirzepatide is also used to treat moderate-to-severe obstructive sleep apnea in adults with obesity.

Not every tirzepatide product is necessarily registered for every indication in every country. Patients in Pakistan should follow the approved labeling of the actual product supplied and their doctor’s prescription.

How Does LuciTirze 7.5mg Injection Work?

Tirzepatide activates two important hormone receptors:

• Glucose-dependent insulinotropic polypeptide (GIP) receptors
• Glucagon-like peptide-1 (GLP-1) receptors

These hormones are involved in blood-glucose regulation and appetite.

Tirzepatide can increase insulin secretion when blood glucose is elevated and reduce inappropriate glucagon secretion. It also delays gastric emptying and can reduce calorie intake by affecting appetite.

These combined actions can improve glycemic control and contribute to body-weight reduction in appropriately selected patients.

LuciTirze 7.5mg Injection Dosage

LuciTirze 7.5mg Injection is not normally the starting strength of tirzepatide treatment.

A commonly established adult dose-escalation schedule starts with:

Starting dose: 2.5mg once weekly.

After 4 weeks, the dose is generally increased to:

5mg once weekly.

If additional treatment effect is required and the medicine is tolerated, the dose may subsequently be increased in 2.5mg increments after at least 4 weeks on the current dose.

This means the treatment sequence may include:

2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg

The maximum recommended adult dosage under established indications is generally 15mg once weekly.

The exact maintenance dose depends on the treatment indication, response, tolerability, and prescribing instructions.

Never start directly with LuciTirze 7.5mg or increase your dose without medical advice.

How to Use LuciTirze 7.5mg Injection

Tirzepatide is given once weekly by subcutaneous injection.

Common injection areas include:

• Abdomen
• Thigh
• Upper arm

Injection sites should be rotated rather than repeatedly injecting into exactly the same location.

The medicine can generally be administered with or without meals and at any time of day.

Use LuciTirze on the same day each week whenever possible.

The exact preparation and injection procedure can vary according to whether the product is supplied as a pen, vial, or another presentation. Always follow the instructions supplied with the actual LuciTirze product.

Do not share an injection pen or needle with another person.

Common Side Effects of LuciTirze 7.5mg

Gastrointestinal effects are among the most common adverse reactions associated with tirzepatide.

Possible side effects include:

• Nausea
• Diarrhea
• Vomiting
• Constipation
• Abdominal pain
• Indigestion
• Reduced appetite
• Burping
• Acid reflux
• Injection-site reactions

Gastrointestinal side effects may be more noticeable during dose escalation.

Gradually increasing the dose helps improve gastrointestinal tolerability, which is one reason patients should not skip directly to a higher strength such as 7.5mg.

Thyroid C-Cell Tumor Warning

Tirzepatide carries an important warning concerning thyroid C-cell tumors.

In studies involving rats, tirzepatide caused thyroid C-cell tumors. It is not known whether tirzepatide causes medullary thyroid carcinoma in humans.

Tirzepatide is contraindicated in patients with:

• A personal history of medullary thyroid carcinoma (MTC)
• A family history of MTC
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

Contact your healthcare professional if you develop a neck lump or swelling, persistent hoarseness, difficulty swallowing, or difficulty breathing.

Pancreatitis Warning

Acute pancreatitis has been reported in patients receiving GLP-1 receptor agonists and tirzepatide.

Seek immediate medical attention if you develop severe or persistent abdominal pain, particularly if the pain radiates toward the back and may or may not occur with vomiting.

If pancreatitis is suspected, tirzepatide should be discontinued and medically evaluated.

Patients with previous pancreatic problems should make sure their doctor knows their complete medical history.

Hypoglycemia

Tirzepatide can increase the risk of hypoglycemia, particularly when combined with insulin or medicines that stimulate insulin secretion, such as sulfonylureas.

Possible symptoms of low blood sugar include:

• Sweating
• Trembling
• Hunger
• Dizziness
• Weakness
• Confusion
• Rapid heartbeat

A doctor may need to reduce the dose of insulin or an insulin secretagogue when tirzepatide is introduced.

Do not change diabetes medicines yourself.

Severe Gastrointestinal Problems

Tirzepatide can cause gastrointestinal adverse reactions that are sometimes severe.

Patients may experience significant nausea, vomiting, diarrhea, or other digestive symptoms.

Tirzepatide is not recommended for certain patients with severe gastroparesis.

Persistent vomiting or diarrhea can also lead to dehydration and contribute to kidney problems.

Contact your healthcare professional if gastrointestinal symptoms become severe or do not improve.

Kidney Problems and Dehydration

Vomiting, nausea, and diarrhea may cause fluid loss.

Significant dehydration can contribute to acute kidney injury, particularly in patients with existing kidney disease or other risk factors.

Drink fluids according to your healthcare professional’s recommendations and seek medical advice if you cannot keep fluids down or develop persistent vomiting or diarrhea.

Kidney-function monitoring may be required when severe gastrointestinal adverse reactions cause volume depletion.

Gallbladder Problems

Tirzepatide treatment has been associated with acute gallbladder disease.

Possible problems include gallstones and inflammation of the gallbladder.

Contact your doctor if you develop:

• Severe upper abdominal pain
• Fever
• Yellowing of the skin or eyes
• Persistent nausea or vomiting

Further gallbladder investigations may be required if cholecystitis or another gallbladder disorder is suspected.

Diabetic Retinopathy

Patients with type 2 diabetes who have a history of diabetic retinopathy should tell their doctor before starting tirzepatide.

Rapid improvements in glucose control can sometimes temporarily worsen diabetic retinopathy.

Patients with a previous history of diabetic eye disease may require appropriate monitoring.

Report sudden visual changes promptly.

Drug Interactions

Tirzepatide delays gastric emptying and may affect the absorption of some medicines taken by mouth.

Tell your doctor or pharmacist about all medicines you use, including:

• Insulin
• Sulfonylureas
• Other diabetes medicines
• Oral medicines with a narrow therapeutic range
• Vitamins and supplements
• Herbal products

Using LuciTirze with another tirzepatide-containing product is not appropriate. Combination with other GLP-1 receptor agonists is also not recommended under the established weight-management labeling.

Oral Contraceptives

Tirzepatide’s effect on gastric emptying may reduce the effectiveness of oral hormonal contraceptives, particularly when treatment begins and following dose escalation.

Women using oral hormonal contraception should discuss appropriate contraceptive measures with their healthcare provider.

A non-oral contraceptive method or additional barrier contraception may be advised for a period after starting tirzepatide and after each dose increase.

Pregnancy and Breastfeeding

Tirzepatide should not be used for weight reduction during pregnancy.

Current prescribing information warns that tirzepatide may cause fetal harm, and treatment for weight reduction should be discontinued when pregnancy is recognized.

Patients who are pregnant, planning pregnancy, or breastfeeding should discuss the potential risks and treatment alternatives with their healthcare professional.

Do not use LuciTirze during pregnancy for weight loss.

Surgery and Anesthesia

Tirzepatide delays gastric emptying.

There have been reports of pulmonary aspiration during general anesthesia or deep sedation in patients receiving GLP-1 receptor agonists.

Tell your surgeon, anesthesiologist, dentist, or other healthcare professional that you are taking tirzepatide before a planned operation or procedure requiring anesthesia or deep sedation.

Your medical team will decide how your medicine should be managed around the procedure.

Storage of LuciTirze 7.5mg Injection

Storage requirements can vary according to the specific LuciTirze presentation.

Follow the temperature and storage instructions printed on the original package.

In general, injectable tirzepatide products require careful storage and should be protected from inappropriate heat, freezing, and excessive light according to the manufacturer’s instructions.

Do not use the injection if:

• It has expired
• Packaging is damaged
• It was stored incorrectly
• The solution looks abnormal according to the product instructions

Do not assume that LuciTirze has exactly the same storage conditions as another tirzepatide brand. Follow the actual product label.

LuciTirze 7.5mg Injection Price in Pakistan

The LuciTirze 7.5mg Injection price in Pakistan can vary according to product presentation, pack size, stock availability, supplier, import costs, and market conditions.

Patients should check the current price rather than relying on an outdated online listing.

You can check the latest LuciTirze 7.5mg Injection price and availability in Pakistan through Impo Medic.

For injectable medicines, correct storage and supply-chain handling are particularly important. Patients should consider authenticity, expiry date, packaging integrity, and storage conditions alongside price.

How to Buy LuciTirze 7.5mg Injection in Pakistan

Patients looking to buy LuciTirze 7.5mg Injection in Pakistan can check current product availability through Impo Medic.

Before purchasing, confirm:

• LuciTirze product name
• Tirzepatide as the active ingredient
• 7.5mg strength
• Correct product presentation
• Original packaging
• Batch information
• Expiry date
• Appropriate storage conditions

Tirzepatide is a prescription treatment and should not be purchased simply for unsupervised weight loss.

A healthcare professional should determine whether tirzepatide is suitable and which dose should be used.

Why Choose Impo Medic?

Impo Medic provides product information and availability support for customers searching for specialist and imported medicines in Pakistan.

For injectable products such as LuciTirze, correct strength, authentic packaging, expiry information, and appropriate storage are particularly important.

Patients can check LuciTirze 7.5mg Injection price and availability in Pakistan at Impo Medic, while decisions about treatment eligibility, starting dose, dose escalation, blood-glucose management, and adverse-effect monitoring should be made by a qualified healthcare professional.

FAQs About LuciTirze 7.5mg Injection (Tirzepatide)

What is LuciTirze 7.5mg Injection used for?

Tirzepatide has approved uses for improving glycemic control in type 2 diabetes and, under specific product indications, chronic weight management. It also has an approved indication for moderate-to-severe obstructive sleep apnea in adults with obesity under appropriate labeling.

Is LuciTirze 7.5mg used for weight loss?

Tirzepatide is approved under specific branded indications for chronic weight management in eligible adults with obesity or overweight plus an associated condition. It should be used with dietary and physical-activity measures and under medical supervision.

Is 7.5mg the starting dose of tirzepatide?

No. Tirzepatide is generally initiated at 2.5mg once weekly. After at least four weeks, the dose is increased to 5mg, and further increases can occur in 2.5mg increments after at least four weeks at the current dose when clinically appropriate.

How often is LuciTirze 7.5mg injected?

Tirzepatide is administered once weekly, not every day.

Where is LuciTirze injected?

Tirzepatide is injected subcutaneously into the abdomen, thigh, or upper arm according to the product instructions.

Can I take tirzepatide with insulin?

Tirzepatide may be prescribed alongside insulin in appropriate patients, but the combination can increase hypoglycemia risk. The treating doctor may need to adjust the insulin dose.

Who should not use tirzepatide?

It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma, MEN 2, or serious hypersensitivity to tirzepatide or relevant product ingredients. Other medical conditions may also affect whether treatment is appropriate.

Where can I check LuciTirze 7.5mg price in Pakistan?

You can check the current LuciTirze 7.5mg Injection price and availability in Pakistan through Impo Medic. Confirm current stock and pricing when ordering.